These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25444294)

  • 21. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decision making by NICE: examining the influences of evidence, process and context.
    Cerri KH; Knapp M; Fernández JL
    Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
    Morrell L; Wordsworth S; Fu H; Rees S; Barker R
    BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intergenerational report misses the point on health spending.
    Duckett S
    Australas J Ageing; 2015 Dec; 34(4):214-6. PubMed ID: 26643227
    [No Abstract]   [Full Text] [Related]  

  • 25. Is the aim of the English health care system to maximize QALYs?
    Shah K; Praet C; Devlin N; Sussex J; Appleby J; Parkin D
    J Health Serv Res Policy; 2012 Jul; 17(3):157-63. PubMed ID: 22767891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extra £2m is needed to improve mental healthcare intelligence, conference hears.
    Limb M
    BMJ; 2015 Feb; 350():h1140. PubMed ID: 25724896
    [No Abstract]   [Full Text] [Related]  

  • 27. Seven years of feast, seven years of famine: boom to bust in the NHS?
    Maynard A; Street A
    BMJ; 2006 Apr; 332(7546):906-8. PubMed ID: 16613969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of health economics in the evaluation of surgery and operative technologies.
    Taylor M
    Surgery; 2017 Feb; 161(2):300-304. PubMed ID: 28096035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bringing health economic modeling to the 21st century.
    Eddy D
    Value Health; 2006; 9(3):168-78. PubMed ID: 16689710
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative health systems. Italy.
    Fausto D
    Adv Health Econ Health Serv Res Suppl; 1990; 1():211-40. PubMed ID: 10113792
    [No Abstract]   [Full Text] [Related]  

  • 31. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.
    Linley WG; Hughes DA
    Health Econ; 2013 Aug; 22(8):948-64. PubMed ID: 22961976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Aspects of health economic evaluations as a contribution to the priority-setting debate in Germany].
    Brüggenjürgen B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Sep; 53(9):890-5. PubMed ID: 20853085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
    Charlton V
    J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can we afford the NHS in future?
    Appleby J
    BMJ; 2011 Jul; 343():d4321. PubMed ID: 21750075
    [No Abstract]   [Full Text] [Related]  

  • 37. Estimating 'costs' for cost-effectiveness analysis.
    Miners A
    Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The NHS: assessing new technologies, NICE and value for money.
    Stevens A; Chalkidou K; Littlejohns P
    Clin Med (Lond); 2011 Jun; 11(3):247-50. PubMed ID: 21902077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
    Charlton V
    Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.